论文部分内容阅读
目的观察银杏叶注射液联合人尿激肽原酶对脑梗死患者临床疗效及安全性。方法急性脑梗死患者60例随机分为两组,对照组:人尿激肽原酶;观察组;银杏叶注射液联合人尿激肽原酶。2组治疗前及治疗后分别观察患者神经功能缺损评分(NIHSS)、血液参数的变化,并进行两组间比较。结果两组治疗后神经功能缺损评分及血液参数差异均有统计学意义(P<0.05)。结论银杏叶注射液联合人尿激肽原酶治疗急性急性脑梗死安全、疗效显著。
Objective To observe the clinical efficacy and safety of Ginkgo biloba injection combined with human kallikrein in patients with cerebral infarction. Methods Sixty patients with acute cerebral infarction were randomly divided into two groups. The control group: human kininogenase; observation group; Ginkgo biloba injection combined with human kallikrein. The changes of neurological deficit score (NIHSS) and blood parameters in two groups before and after treatment were observed and compared between the two groups. Results After treatment, neurological deficit scores and blood parameters were significantly different (P <0.05). Conclusion Ginkgo biloba injection combined with human kallikrein in the treatment of acute acute cerebral infarction is safe and effective.